Noncompaction cardiomyopathy medical therapy: Difference between revisions
No edit summary |
|||
(5 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of [[angiotensin-converting enzyme|ACE inhibitors]], [[Beta blocker|beta blockers]] and [[aspirin]]. | The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of [[angiotensin-converting enzyme|ACE inhibitors]], [[Beta blocker|beta blockers]] and [[aspirin]]<ref>Botto, LD. Left ventricular noncompaction. Orphanet encyclopedia. http://www.orpha.net/data/patho/GB/uk-LVNC.pdf </ref>. | ||
==Antiplatelet Therapy== | ==Antiplatelet Therapy== | ||
Given the risk of [[embolization]], | Given the risk of [[embolization]], all patients with NCC are generally treated with prophylactic [[aspirin]]. | ||
==Beta Blockade== | ==Beta Blockade== | ||
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. | Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. The impact of [[Carvedilol]] on left ventricular function has been reported <ref>Toyono M, Kondo C, Nakajima Y, et al. Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart. 2001; 86: e4–e6.</ref>. | ||
==Angiotensin Converting Enzyme (ACE) Inhibition== | ==Angiotensin Converting Enzyme (ACE) Inhibition== | ||
Similar to other [[cardiomyopathies]], ACE inhibitors are indicated given the low [[cardiac output]] in these patients. | Similar to other [[cardiomyopathies]], ACE inhibitors are indicated given the low [[cardiac output]] in these patients. | ||
==Calcium Channel Blockade== | |||
[[Calcium channel blockers]] may be of benefit in those patients with apical hypertrophy and no reduction in systolic contractility. | |||
==Patients with Mitochondrial Abnormalities== | |||
Some groups have recommended the use of [[Coenzyme Q10]], [[riboflavin]], [[thiamine]] and [[carnitine]] in these patients. | |||
==References== | ==References== | ||
Line 19: | Line 26: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Overview complete]] | [[Category:Overview complete]] | ||
[[Category:Template complete]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 14:45, 7 August 2011
Noncompaction Cardiomyopathy Microchapters |
Pathophysiology |
---|
Differentiating Noncompaction Cardiomyopathy from other Diseases |
Diagnosis |
Treatment |
Noncompaction cardiomyopathy medical therapy On the Web |
Risk calculators and risk factors for Noncompaction cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of ACE inhibitors, beta blockers and aspirin[1].
Antiplatelet Therapy
Given the risk of embolization, all patients with NCC are generally treated with prophylactic aspirin.
Beta Blockade
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. The impact of Carvedilol on left ventricular function has been reported [2].
Angiotensin Converting Enzyme (ACE) Inhibition
Similar to other cardiomyopathies, ACE inhibitors are indicated given the low cardiac output in these patients.
Calcium Channel Blockade
Calcium channel blockers may be of benefit in those patients with apical hypertrophy and no reduction in systolic contractility.
Patients with Mitochondrial Abnormalities
Some groups have recommended the use of Coenzyme Q10, riboflavin, thiamine and carnitine in these patients.
References
- ↑ Botto, LD. Left ventricular noncompaction. Orphanet encyclopedia. http://www.orpha.net/data/patho/GB/uk-LVNC.pdf
- ↑ Toyono M, Kondo C, Nakajima Y, et al. Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart. 2001; 86: e4–e6.